"While a recent observational study suggests estrogen-only hormone therapy may be linked to fewer Alzheimer’s hallmarks in autopsied brains, current clinical guidance and expert recommendations do not support its use for cognitive decline prevention. Understanding the limitations of observational data and the established evidence base is crucial for informed decision-making."
A recent observational study has ignited renewed discussion around the potential impact of estrogen-only hormone therapy (HT) on Alzheimer’s disease. The findings, which indicated a lower prevalence of Alzheimer’s pathology in the brains of women who had used this therapy, have led some to question whether it could be a strategy for cognitive protection. However, this single study, while intriguing, exists within a broader landscape of established medical guidance and a different body of evidence that paints a more nuanced picture. Official recommendations from leading health organizations have not changed, underscoring the importance of consulting established guidelines and one’s clinician for personalized advice. Understanding the context surrounding this new research, including its observational nature and the existing consensus on HT, is far more beneficial than focusing solely on the headline findings.
The conversation around hormone therapy and cognitive health is not new, but it is continuously evolving. The World Health Organization (WHO), just weeks before the publication of the latest study, issued updated guidelines on dementia risk reduction. These guidelines, which meticulously reviewed existing evidence, concluded that menopausal hormone therapy lacks sufficient evidence to support its use for preventing cognitive decline. This assessment was based on a comprehensive review of data involving over a million participants, which found no conclusive evidence that hormone therapy, in general, either increases or decreases dementia risk. Consequently, the WHO emphasizes that decisions regarding HT prescription should be primarily based on its other established benefits and risks, such as managing menopausal symptoms and bone health.
Professional bodies in endocrinology and menopause have echoed and even strengthened this stance. The European Society of Endocrinology explicitly recommends against the use of hormone therapy for the prevention or treatment of dementia. Similarly, The Menopause Society’s position statement clearly states that hormone therapy is not recommended at any age for the purpose of preventing or treating cognitive decline. This consistent, expert-driven guidance forms the bedrock of current clinical practice and patient care.
This established guidance now sits alongside a significant development from the U.S. Food and Drug Administration (FDA). Earlier this year, the FDA approved the first six product labels for menopausal hormone therapy, a move that included the removal of risk statements related to cardiovascular disease, breast cancer, and probable dementia from the boxed warnings. This decision, while appearing contradictory to the cautionary expert guidance, is critical to understand. The FDA’s action was based on a re-evaluation of the evidence, concluding that the previously highlighted risks were not as definitively linked to hormone therapy as once feared, particularly when used within specific parameters. However, crucially, this labeling change did not add dementia prevention as an approved indication for hormone therapy. The result is a complex and evolving landscape: a significant warning was withdrawn, expert bodies continue to advise against using HT for brain protection, and a striking observational finding has emerged, all within a relatively short timeframe.
The study that has sparked this renewed interest was conducted by researchers at Stanford Medicine. Analyzing data from two large Alzheimer’s databases, encompassing the medical records and post-mortem brain examinations of 21,462 women, the researchers were notably clear about the scope and limitations of their work. Their findings revealed that among women whose brains were examined after death, those who had used estrogen-only hormone therapy exhibited a 35% lower likelihood of showing the characteristic hallmarks of Alzheimer’s disease, specifically amyloid plaques and tau tangles. Furthermore, when considering a broader analysis that included clinical diagnoses made during participants’ lives, HT users had a 39% lower odds of a clinical dementia diagnosis. Biomarker measurements, taken while the participants were alive, also suggested a similar protective trend.
Senior author Hadi Hosseini highlighted the unique contribution of their research, emphasizing that "no one has previously looked at substantial numbers of postmortem Alzheimer’s disease outcomes." The Stanford Medicine summary of the study frames the work as addressing a genuinely contested question in the field, and the published paper itself describes the observed associations as statistically significant, albeit small. Co-lead author Jennifer Bruno was equally forthright in delineating the study’s boundaries, characterizing the results as a "signal for further study rather than a reason for anyone to start or stop hormone therapy for brain health." This clarity is paramount because the study’s design was observational. This means it can identify associations between variables, but it cannot establish a cause-and-effect relationship. In simpler terms, it cannot definitively prove that estrogen-only therapy caused the reduction in Alzheimer’s hallmarks or dementia diagnoses.
The strongest reason for caution and a crucial counterpoint to the observational findings comes from a different, more robust type of scientific evidence: randomized controlled trials (RCTs). Independent researchers and experts point to conflicting data from these trials. Pauline Maki, a professor of psychiatry, psychology, and obstetrics and gynecology at the University of Illinois Chicago, who was not involved in the Stanford study, articulated this concern. She explained to Medscape Medical News that randomized data directly conflict with the new study’s conclusions. Maki referenced a significant analysis from the Women’s Health Initiative (WHI), a large-scale RCT, which found no discernible differences in Alzheimer’s biomarkers between women randomly assigned to hormone therapy and those assigned to a placebo.
The critical advantage of randomized assignment is its ability to control for pre-existing differences between individuals who choose to participate in a treatment group versus a control group. These pre-existing differences, often referred to as "healthy user bias," can significantly confound the results of observational studies. Women who choose to use hormone therapy, for instance, may historically differ from non-users in various ways that independently influence their health outcomes. These differences can include greater access to healthcare, higher levels of education, and better baseline cardiovascular health. Maki further noted that population-wide databases from countries with more equitable healthcare access, such as Scandinavian nations and Taiwan, have not demonstrated a reduced risk of Alzheimer’s disease associated with hormone therapy, further questioning the generalizability of the observational findings.
Beyond the statistical considerations, there are practical aspects of the study population that warrant attention. The estrogen-only therapy examined in the study is specifically prescribed to women who have undergone a hysterectomy. This is because estrogen, when taken without a progestogen, carries an increased risk of endometrial cancer in women who still have a uterus. This crucial warning remains on all systemic estrogen-only products. The participants in the Stanford study averaged around 70 years of age. This age is generally outside the window that current labeling emphasizes for initiating hormone therapy, which typically recommends starting within 10 years of menopause onset or before age 60. Moreover, the findings of this particular study do not extend to combined estrogen and progestogen regimens, which are more commonly used by women who have not had a hysterectomy, nor do they apply to topical formulations of estrogen, which are absorbed differently and have different systemic effects.
Therefore, the decision that most women face this year regarding hormone therapy is not about whether the scientific debate is definitively settled, but rather what questions to raise during their next medical appointment. Current clinical practice dictates that hormone therapy is primarily prescribed for the relief of menopausal symptoms such as hot flashes, night sweats, and genitourinary symptoms, as well as for bone protection in appropriate candidates. It is explicitly not prescribed as a preventative measure for dementia. Neither the recent FDA labeling changes nor the new autopsy findings have altered this fundamental clinical approach.
The federal announcement that initiated the removal of the boxed warnings for hormone therapy products clarified that the labeled recommendation would be to initiate systemic therapy within 10 years of menopause onset or before age 60. This specific timing guidance represents the most concrete piece of information a patient can bring to a discussion with their clinician. When considering hormone therapy, a woman and her doctor should discuss a range of factors, including: whether her menopausal symptoms are severe enough to warrant treatment; whether she has had a hysterectomy, which would determine the appropriate formulation; her personal medical history, including any history of blood clots, stroke, liver disease, or hormone-sensitive cancers, which can impact candidacy; and whether a transdermal patch or gel might be preferable to oral pills, given potential differences in risk profiles.
It is imperative that no individual starts, stops, or alters a prescription based solely on a study summary or a news report about a label change. Women who are currently taking hormone therapy and have concerns arising from conflicting media coverage should discuss these issues with their healthcare provider at a scheduled appointment rather than discontinuing their medication independently. Abruptly stopping HT can lead to a return or worsening of menopausal symptoms.
MedicalDaily previously reported on the autopsy findings and their limitations when the study was initially published. This expanded report aims to provide the crucial surrounding context of existing guidance and labeling regulations, which are the practical determinants of what a clinician can and should act upon. Several critical questions remain unanswered and highlight the need for further research. The Stanford study, for instance, did not capture when women began their hormone therapy, how long they continued it, or whether they switched between different formulations. The study also did not examine whether combined estrogen and progestogen therapy, which is the more common regimen during perimenopause and for women with a uterus, carries any similar associations with reduced Alzheimer’s pathology, as too few autopsied women had used it. Furthermore, whether starting hormone therapy closer to the onset of menopause, rather than in later life, alters any potential protective effects remains untested.
The researchers involved in the Stanford study have themselves called for prospective, biomarker-based trials that would follow women longitudinally before, during, and after menopause. Such trials are essential for establishing causality and understanding the long-term effects of hormone therapy on cognitive health. However, no such comprehensive trial has yet reported results, and none are expected in the immediate future.
For now, the practical summary remains narrow and grounded in established medical consensus. The autopsy evidence, while real and adding a new line of inquiry to a contested field, is not a sufficient basis for prescribing hormone therapy for dementia risk reduction. The current WHO guideline document and the systematic review that informed it both fall short of endorsing hormone therapy for this purpose. Ultimately, the decision regarding hormone therapy rests with a woman and her clinician, and it remains a decision primarily focused on managing menopausal symptoms, considering the timing of treatment initiation, and evaluating an individual’s personal risk factors and health profile.
